Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Jose Carlos Florez, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Jose Florez and Paul Franks.
Connection Strength

4.134
  1. Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. Diabetes Care. 2013 May; 36(5):1413-21.
    View in: PubMed
    Score: 0.551
  2. Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 09; 63(9):1671-1693.
    View in: PubMed
    Score: 0.229
  3. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 07; 43(7):1617-1635.
    View in: PubMed
    Score: 0.226
  4. Quality of dietary fat and genetic risk of type 2 diabetes: individual participant data meta-analysis. BMJ. 2019 07 25; 366:l4292.
    View in: PubMed
    Score: 0.212
  5. A Global Overview of Precision Medicine in Type 2 Diabetes. Diabetes. 2018 10; 67(10):1911-1922.
    View in: PubMed
    Score: 0.201
  6. Season-dependent associations of circadian rhythm-regulating loci (CRY1, CRY2 and MTNR1B) and glucose homeostasis: the GLACIER Study. Diabetologia. 2015 May; 58(5):997-1005.
    View in: PubMed
    Score: 0.156
  7. Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program. Diabetologia. 2014 Mar; 57(3):485-90.
    View in: PubMed
    Score: 0.144
  8. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One. 2012; 7(9):e44424.
    View in: PubMed
    Score: 0.132
  9. Genetic predisposition to long-term nondiabetic deteriorations in glucose homeostasis: Ten-year follow-up of the GLACIER study. Diabetes. 2011 Jan; 60(1):345-54.
    View in: PubMed
    Score: 0.115
  10. Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2008 Dec; 51(12):2214-23.
    View in: PubMed
    Score: 0.100
  11. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia. 2008 Mar; 51(3):451-7.
    View in: PubMed
    Score: 0.095
  12. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2007 Dec; 50(12):2451-60.
    View in: PubMed
    Score: 0.093
  13. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb; 56(2):531-6.
    View in: PubMed
    Score: 0.089
  14. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021 06; 53(6):840-860.
    View in: PubMed
    Score: 0.060
  15. Publisher Correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nat Commun. 2021 Feb 08; 12(1):995.
    View in: PubMed
    Score: 0.059
  16. Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme. Diabetes Obes Metab. 2021 04; 23(4):1030-1040.
    View in: PubMed
    Score: 0.059
  17. Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nat Commun. 2021 01 05; 12(1):24.
    View in: PubMed
    Score: 0.059
  18. Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors. Diabetes. 2020 01; 69(1):112-120.
    View in: PubMed
    Score: 0.054
  19. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2019 Jul; 51(7):1191-1192.
    View in: PubMed
    Score: 0.053
  20. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nat Genet. 2019 03; 51(3):452-469.
    View in: PubMed
    Score: 0.051
  21. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2018 05; 50(5):765-766.
    View in: PubMed
    Score: 0.049
  22. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2018 05; 50(5):766-767.
    View in: PubMed
    Score: 0.049
  23. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet. 2018 04; 50(4):559-571.
    View in: PubMed
    Score: 0.048
  24. Erratum: Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Sci Data. 2018 01 23; 5:180002.
    View in: PubMed
    Score: 0.048
  25. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2018 01; 50(1):26-41.
    View in: PubMed
    Score: 0.048
  26. Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Sci Data. 2017 12 19; 4:170179.
    View in: PubMed
    Score: 0.047
  27. Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. J Clin Endocrinol Metab. 2017 08 01; 102(8):2678-2689.
    View in: PubMed
    Score: 0.046
  28. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017 11; 66(11):2888-2902.
    View in: PubMed
    Score: 0.046
  29. A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes. 2017 07; 66(7):2019-2032.
    View in: PubMed
    Score: 0.045
  30. Rare and low-frequency coding variants alter human adult height. Nature. 2017 02 09; 542(7640):186-190.
    View in: PubMed
    Score: 0.045
  31. Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program. Psychosom Med. 2017 Feb/Mar; 79(2):224-233.
    View in: PubMed
    Score: 0.045
  32. FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. BMJ. 2016 Sep 20; 354:i4707.
    View in: PubMed
    Score: 0.044
  33. The genetic architecture of type 2 diabetes. Nature. 2016 08 04; 536(7614):41-47.
    View in: PubMed
    Score: 0.043
  34. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015 Dec; 47(12):1415-25.
    View in: PubMed
    Score: 0.041
  35. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.041
  36. Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. Diabetes. 2015 Dec; 64(12):4312-21.
    View in: PubMed
    Score: 0.040
  37. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun. 2015 Jan 29; 6:5897.
    View in: PubMed
    Score: 0.039
  38. Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care. 2014 Oct; 37(10):2738-45.
    View in: PubMed
    Score: 0.037
  39. The influence of rare genetic variation in SLC30A8 on diabetes incidence and ß-cell function. J Clin Endocrinol Metab. 2014 May; 99(5):E926-30.
    View in: PubMed
    Score: 0.036
  40. Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. Diabetes Care. 2014 Apr; 37(4):909-11.
    View in: PubMed
    Score: 0.036
  41. Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program. Obesity (Silver Spring). 2013 Sep; 21(9):E520-6.
    View in: PubMed
    Score: 0.035
  42. Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet Med. 2012 Dec; 29(12):1579-88.
    View in: PubMed
    Score: 0.033
  43. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet. 2012; 8(8):e1002895.
    View in: PubMed
    Score: 0.033
  44. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012 Sep; 44(9):991-1005.
    View in: PubMed
    Score: 0.033
  45. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012 May 13; 44(6):659-69.
    View in: PubMed
    Score: 0.032
  46. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012; 8(3):e1002607.
    View in: PubMed
    Score: 0.032
  47. No interactions between previously associated 2-hour glucose gene variants and physical activity or BMI on 2-hour glucose levels. Diabetes. 2012 May; 61(5):1291-6.
    View in: PubMed
    Score: 0.032
  48. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One. 2012; 7(1):e29202.
    View in: PubMed
    Score: 0.031
  49. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care. 2012 Feb; 35(2):363-6.
    View in: PubMed
    Score: 0.031
  50. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov; 8(11):e1001116.
    View in: PubMed
    Score: 0.031
  51. Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. Diabetes. 2011 Sep; 60(9):2407-16.
    View in: PubMed
    Score: 0.031
  52. TCF7L2 polymorphism, weight loss and proinsulin:insulin ratio in the diabetes prevention program. PLoS One. 2011; 6(7):e21518.
    View in: PubMed
    Score: 0.030
  53. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011 Apr; 60(4):1340-8.
    View in: PubMed
    Score: 0.030
  54. Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care. 2010 Dec; 33(12):2684-91.
    View in: PubMed
    Score: 0.028
  55. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010 Oct; 59(10):2672-81.
    View in: PubMed
    Score: 0.028
  56. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010 Feb; 42(2):105-16.
    View in: PubMed
    Score: 0.027
  57. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008 Sep; 57(9):2503-10.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.